About BioLineRx Ltd.
https://www.biolinerx.comBioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology.
CEO
Philip A. Serlin
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public July 27, 2011
Method of going public IPO
Full time employees 28
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-01-30 | Reverse | 1:40 |
| 2019-07-15 | Reverse | 1:15 |
Ratings Snapshot
Rating : C
Discounted Cash Flow 5
Return On Equity 1
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 2
Most Recent Analyst Grades
Grade Summary
Buy 2
Showing Top 2 of 2
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Institutional Ownership
CVI HOLDINGS, LLC
Shares:815.68K
Value:$2.34M
ACT CAPITAL MANAGEMENT, LLC
Shares:27.5K
Value:$78.92K
CETERA ADVISORS LLC
Shares:10.55K
Value:$30.28K
Summary
% Of Shares Owned 19.90%
Total Number Of Holders 7
Showing Top 3 of 7
Market Cap $12.97 M
52w High $7.77
52w Low $2.30
P/E -0.48
Volume 16.37K
Outstanding Shares 4.35M
About BioLineRx Ltd.
https://www.biolinerx.comBioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $4.94M ▲ | $-7.95M ▼ | $-5.82M ▼ | -117.78% ▲ | $-1.47 ▼ | $0 ▲ |
| Q2-2025 | $304K ▲ | $2.54M ▼ | $-3.94M ▼ | -1.3K% ▼ | $-1 ▼ | $-3.49M ▼ |
| Q1-2025 | $255K ▼ | $2.61M ▼ | $5.13M ▲ | 2.01K% ▲ | $0.06 ▲ | $5.71M ▲ |
| Q4-2024 | $11.75M ▲ | $10.09M ▲ | $-3.19M ▲ | -27.13% ▲ | $-0.04 ▲ | $3.1M ▲ |
| Q3-2024 | $4.94M | $9.51M | $-5.82M | -117.78% | $-0.07 | $-3.36M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $28.16M ▲ | $43.27M ▼ | $23.2M ▲ | $20.07M ▼ |
| Q1-2025 | $26.37M ▲ | $43.51M ▲ | $22.65M ▼ | $20.86M ▲ |
| Q4-2024 | $19.56M ▼ | $38.91M ▼ | $25.45M ▼ | $13.46M ▲ |
| Q3-2024 | $29.17M ▼ | $52.74M ▼ | $44.24M ▼ | $8.51M ▼ |
| Q2-2024 | $40.06M | $64.6M | $50.62M | $13.98M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $-3.94M ▼ | $-177K ▲ | $-3.7M ▲ | $1.6M ▼ | $-1.85M ▼ | $-177K ▲ |
| Q1-2025 | $5.13M ▲ | $-2.59M ▲ | $-8.18M ▼ | $9.45M ▲ | $-1.4M ▼ | $-2.59M ▲ |
| Q4-2024 | $-3.19M ▲ | $-8.61M ▲ | $11.16M ▲ | $-1.11M ▲ | $1.6M ▲ | $-8.61M ▲ |
| Q3-2024 | $-5.82M ▼ | $-9.82M ▲ | $10.18M ▲ | $-1.22M ▼ | $-787K ▼ | $-9.82M ▲ |
| Q2-2024 | $484K | $-11.33M | $-8.64M | $23.88M | $3.63M | $-11.36M |
CEO
Philip A. Serlin
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public July 27, 2011
Method of going public IPO
Full time employees 28
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-01-30 | Reverse | 1:40 |
| 2019-07-15 | Reverse | 1:15 |
Ratings Snapshot
Rating : C
Discounted Cash Flow 5
Return On Equity 1
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 2
Most Recent Analyst Grades
Grade Summary
Buy 2
Showing Top 2 of 2
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Institutional Ownership
CVI HOLDINGS, LLC
Shares:815.68K
Value:$2.34M
ACT CAPITAL MANAGEMENT, LLC
Shares:27.5K
Value:$78.92K
CETERA ADVISORS LLC
Shares:10.55K
Value:$30.28K
Summary
% Of Shares Owned 19.90%
Total Number Of Holders 7
Showing Top 3 of 7